-
公开(公告)号：WO2011119008A2
公开(公告)日：2011-09-29
申请号：PCT/KR2011/002080
申请日：2011-03-25
Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SOOKMYUNG WOMEN'S UNIVERSITY , IL-YANG PHARM. CO., LTD , SAMSUNGN LIFE WELFARE FOUNDATION , CHO, Dae Ho , BANG, Sa Ik , PARK, Jeong Min , YOON, Sun Young , KIM, Sang Yoon , LEE, Ha Rum , PARK, Yoo Rim , SON Juah
Inventor： CHO, Dae Ho , BANG, Sa Ik , PARK, Jeong Min , YOON, Sun Young , KIM, Sang Yoon , LEE, Ha Rum , PARK, Yoo Rim , SON Juah
CPC classification number: C07K7/06 , A61K38/00 , A61L27/227 , C07K5/1008
Abstract: The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial-skin and preparation of blood vessels for transplantation.
Abstract translation: 本发明涉及促进血管生成的肽及其新用途。 更具体地，本发明涉及促进血管发生的肽，以及该肽用于促进血管发生和预防或治疗血管发生相关疾病的用途。 本发明的肽对促进血管生成具有极好的效果。 因此，用于预防或治疗血管生成相关疾病和用于制备皮瓣，伤口和烧伤愈合的再生，人造皮肤的植入和用于移植的血管的制备是有用的。
-
2.发明申请NOVEL USE OF ERYTHROID DIFFERENTIATION REGULATOR 1 AS AN AGENT FOR TREATING CANCER 审中-公开艾滋病毒分化调节剂1作为治疗癌症的药物的新用途
公开(公告)号：WO2011118981A2
公开(公告)日：2011-09-29
申请号：PCT/KR2011001999
申请日：2011-03-23
Applicant: INDUSTRY ACADEMIC COOPERATION FOUNDATION SOOKMYUNG WOMEN S UNIVERSITY , IL YANG PHARM CO LTD , SAMSUNGN LIFE WELFARE FOUNDATION , CHO DAE HO , BANG SA IK , PARK JEONG MIN , JUNG MIN KYUNG , LEE HA RUM , PARK YOO RIM , PARK SEUNG BEOM , SON JUAH , HOUH YOUN KYUNG
Inventor： CHO DAE HO , BANG SA IK , PARK JEONG MIN , JUNG MIN KYUNG , LEE HA RUM , PARK YOO RIM , PARK SEUNG BEOM , SON JUAH , HOUH YOUN KYUNG
CPC classification number: A61K38/1709 , A61K48/00 , C07K14/4702
Abstract: The present invention relates to a novel use of erythroid differentiation regulator 1 (Erdrl) as an agent for treating cancer. More particularly, it relates to an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and inhibiting cancer metastasis, an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and treating cancer, an use of an antibody specific for Erdrl for diagnosing cancer, or a method for screening agents for regulating cancer metastasis or cancer cells migration. The Erdrl is negatively regulated by IL-18 expression and it suppresses migration, invasion and metastasis of cancer or tumor cell by expression of HSP90 and generation of ROI. And an Erdrl recombinant protein promotes NK-cell killing activity against cancer cell. Accordingly, the Erdrl and an expression vector comprising polynucleotide encoding the same and recombinant protein suppress cancer metastasis and bring an effect on activation of immune cells, and therefore can be useful for preventing, treating and diagnosing cancer.
Abstract translation: 本发明涉及红细胞分化调节剂1（Erdrl）作为癌症治疗剂的新用途。 更具体地，涉及使用Erdr1或包含编码该多核苷酸的表达载体来预防和抑制癌症转移，使用Erdr1或包含编码该多核苷酸的表达载体来预防和治疗癌症的用途 用于诊断癌症的Erdr1特异性抗体，或用于筛选用于调节癌症转移或癌细胞迁移的试剂的方法。 Erdr1被IL-18表达负调节，并通过HSP90的表达和ROI的产生来抑制癌症或肿瘤细胞的迁移，侵袭和转移。 并且Erdrl重组蛋白促进针对癌细胞的NK细胞杀伤活性。 因此，Erdr1和包含编码该多核苷酸的多核苷酸的表达载体和重组蛋白抑制癌症转移并对免疫细胞的活化产生影响，因此可用于预防，治疗和诊断癌症。
-
公开(公告)号：WO2010041863A3
公开(公告)日：2010-09-16
申请号：PCT/KR2009005714
申请日：2009-10-07
Applicant: IND ACADEMIC COOP , SAMSUNG LIFE WELFARE FOUND , CHO DAE HO , BANG SA IK , SONG SEOK BEAN , CHEON SO YOUNG , JUNG MIN KYUNG , PARK YOO RIM
Inventor： CHO DAE HO , BANG SA IK , SONG SEOK BEAN , CHEON SO YOUNG , JUNG MIN KYUNG , PARK YOO RIM
IPC: C12N5/077
CPC classification number: C12N5/0653 , C12N2500/25 , C12N2501/39 , C12N2501/82
Abstract: The present invention relates to an adipocyte differentiation medium composition and a method of differentiating preadipocytes into adipocytes using the same. The adipocyte differentiation medium composition is characterised in that it comprises insulin, DHEA (dehydroepiandrosterone) and histamine. Said medium composition achieves smoother distribution and more stable settling of differentiated adipocytes in comparison with conventional adipocyte differentiation medium compositions, thereby maximising adipocytic cell viability. Furthermore, the DHEA and histamine used in said medium composition is more cost-efficient than conventional adipocyte differentiation medium compositions that rely on dexamethasone and isobutylmethylxanthine.
Abstract translation: 本发明涉及脂肪细胞分化培养基组合物和使用该组合物将前脂肪细胞分化成脂肪细胞的方法。 脂肪细胞分化培养基组合物的特征在于它包含胰岛素，DHEA（脱氢表雄酮）和组胺。 与常规脂肪细胞分化培养基组合物相比，所述培养基组合物实现了分化的脂肪细胞的更平滑的分布和更稳定的沉降，从而使脂肪细胞活力最大化。 此外，用于所述培养基组合物中的DHEA和组胺比依靠地塞米松和异丁基甲基黄嘌呤的常规脂肪细胞分化培养基组合物更具成本效益。
-
4.发明申请NOVEL USE OF ERYTHROID DIFFERENTIATION REGULATOR 1 AS AN AGENT FOR TREATING CANCER 审中-公开艾滋病毒分化调节剂1作为治疗癌症的药物的新用途
公开(公告)号：WO2011118981A9
公开(公告)日：2012-03-15
申请号：PCT/KR2011001999
申请日：2011-03-23
Applicant: INDUSTRY ACADEMIC COOPERATION FOUNDATION SOOKMYUNG WOMEN S UNIVERSITY , IL YANG PHARM CO LTD , SAMSUNGN LIFE WELFARE FOUNDATION , CHO DAE HO , BANG SA IK , PARK JEONG MIN , JUNG MIN KYUNG , LEE HA RUM , PARK YOO RIM , PARK SEUNG BEOM , SON JUAH , HOUH YOUN KYUNG
Inventor： CHO DAE HO , BANG SA IK , PARK JEONG MIN , JUNG MIN KYUNG , LEE HA RUM , PARK YOO RIM , PARK SEUNG BEOM , SON JUAH , HOUH YOUN KYUNG
CPC classification number: A61K38/1709 , A61K48/00 , C07K14/4702
Abstract: The present invention relates to a novel use of erythroid differentiation regulator 1 (Erdrl) as an agent for treating cancer. More particularly, it relates to an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and inhibiting cancer metastasis, an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and treating cancer, an use of an antibody specific for Erdrl for diagnosing cancer, or a method for screening agents for regulating cancer metastasis or cancer cells migration. The Erdrl is negatively regulated by IL-18 expression and it suppresses migration, invasion and metastasis of cancer or tumor cell by expression of HSP90 and generation of ROI. And an Erdrl recombinant protein promotes NK-cell killing activity against cancer cell. Accordingly, the Erdrl and an expression vector comprising polynucleotide encoding the same and recombinant protein suppress cancer metastasis and bring an effect on activation of immune cells, and therefore can be useful for preventing, treating and diagnosing cancer.
Abstract translation: 本发明涉及红细胞分化调节剂1（Erdrl）作为癌症治疗剂的新用途。 更具体地，涉及使用Erdr1或包含编码该多核苷酸的表达载体来预防和抑制癌症转移，使用Erdr1或包含编码该多核苷酸的表达载体来预防和治疗癌症的用途 用于诊断癌症的Erdr1特异性抗体，或用于筛选用于调节癌症转移或癌细胞迁移的试剂的方法。 Erdr1被IL-18表达负调节，并通过HSP90的表达和ROI的产生来抑制癌症或肿瘤细胞的迁移，侵袭和转移。 并且Erdrl重组蛋白促进针对癌细胞的NK细胞杀伤活性。 因此，Erdr1和包含编码该多核苷酸的多核苷酸的表达载体和重组蛋白抑制癌症转移并对免疫细胞的活化产生影响，因此可用于预防，治疗和诊断癌症。
-
公开(公告)号：WO2010041863A8
公开(公告)日：2010-07-29
申请号：PCT/KR2009005714
申请日：2009-10-07
Applicant: IND ACADEMIC COOP , SAMSUNG LIFE WELFARE FOUND , CHO DAE HO , BANG SA IK , SONG SEOK BEAN , CHEON SO YOUNG , JUNG MIN KYUNG , PARK YOO RIM
Inventor： CHO DAE HO , BANG SA IK , SONG SEOK BEAN , CHEON SO YOUNG , JUNG MIN KYUNG , PARK YOO RIM
IPC: C12N5/077
CPC classification number: C12N5/0653 , C12N2500/25 , C12N2501/39 , C12N2501/82
Abstract: The present invention relates to an adipocyte differentiation medium composition and a method of differentiating preadipocytes into adipocytes using the same. The adipocyte differentiation medium composition is characterised in that it comprises insulin, DHEA (dehydroepiandrosterone) and histamine. Said medium composition achieves smoother distribution and more stable settling of differentiated adipocytes in comparison with conventional adipocyte differentiation medium compositions, thereby maximising adipocytic cell viability. Furthermore, the DHEA and histamine used in said medium composition is more cost-efficient than conventional adipocyte differentiation medium compositions that rely on dexamethasone and isobutylmethylxanthine.
-
Patent Agency Ranking
公开(公告)号：WO2011119009A3
公开(公告)日：2012-04-05
申请号：PCT/KR2011002081
申请日：2011-03-25
Applicant: INDUSTRY ACADEMIC COOPERATION FOUNDATION SOOKMYUNG WOMEN S UNIVERSITY , IL YANG PHARM CO LTD , SAMSUNGN LIFE WELFARE FOUNDATION , CHO DAE HO , BANG SA IK , PARK JEONG MIN , YOON SUN YOUNG , KIM SANG YOON , LEE HA RUM , PARK YOO RIM , SON JUAH
Inventor： CHO DAE HO , BANG SA IK , PARK JEONG MIN , YOON SUN YOUNG , KIM SANG YOON , LEE HA RUM , PARK YOO RIM , SON JUAH
CPC classification number: A61K38/08 , A61K38/00 , A61K38/07 , C07K5/10 , C07K5/101 , C07K7/06 , C07K2319/00 , C07K2319/50
Abstract: The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial skin and preparation of blood vessels for transplantation.
Abstract translation: 本发明涉及促进血管生成的肽及其新用途。 更具体地，本发明涉及促进血管生成的肽，以及该肽用于促进血管发生和预防或治疗血管发生相关疾病的用途。 本发明的肽对促进血管生成具有极好的效果。 因此，用于预防或治疗血管生成相关疾病和用于制备皮瓣，伤口和烧伤愈合的再生，植入人造皮肤和制备用于移植的血管是有用的。
-
公开(公告)号：WO2011118981A3
公开(公告)日：2011-09-29
申请号：PCT/KR2011/001999
申请日：2011-03-23
Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SOOKMYUNG WOMEN'S UNIVERSITY , IL-YANG PHARM. CO., LTD , SAMSUNGN LIFE WELFARE FOUNDATION , CHO, Dae Ho , BANG, Sa Ik , PARK, Jeong Min , JUNG, Min Kyung , LEE, Ha Rum , PARK, Yoo Rim , PARK, Seung Beom , SON, Juah , HOUH, Youn Kyung
Inventor： CHO, Dae Ho , BANG, Sa Ik , PARK, Jeong Min , JUNG, Min Kyung , LEE, Ha Rum , PARK, Yoo Rim , PARK, Seung Beom , SON, Juah , HOUH, Youn Kyung
Abstract: The present invention relates to a novel use of erythroid differentiation regulator 1 (Erdrl) as an agent for treating cancer. More particularly, it relates to an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and inhibiting cancer metastasis, an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and treating cancer, an use of an antibody specific for Erdrl for diagnosing cancer, or a method for screening agents for regulating cancer metastasis or cancer cells migration. The Erdrl is negatively regulated by IL-18 expression and it suppresses migration, invasion and metastasis of cancer or tumor cell by expression of HSP90 and generation of ROI. And an Erdrl recombinant protein promotes NK-cell killing activity against cancer cell. Accordingly, the Erdrl and an expression vector comprising polynucleotide encoding the same and recombinant protein suppress cancer metastasis and bring an effect on activation of immune cells, and therefore can be useful for preventing, treating and diagnosing cancer.
-
公开(公告)号：WO2011119008A3
公开(公告)日：2012-04-26
申请号：PCT/KR2011002080
申请日：2011-03-25
Applicant: INDUSTRY ACADEMIC COOPERATION FOUNDATION SOOKMYUNG WOMEN S UNIVERSITY , IL YANG PHARM CO LTD , SAMSUNGN LIFE WELFARE FOUNDATION , CHO DAE HO , BANG SA IK , PARK JEONG MIN , YOON SUN YOUNG , KIM SANG YOON , LEE HA RUM , PARK YOO RIM , SON JUAH
Inventor： CHO DAE HO , BANG SA IK , PARK JEONG MIN , YOON SUN YOUNG , KIM SANG YOON , LEE HA RUM , PARK YOO RIM , SON JUAH
CPC classification number: C07K7/06 , A61K38/00 , A61L27/227 , C07K5/1008
Abstract: The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial-skin and preparation of blood vessels for transplantation.
Abstract translation: 本发明涉及促进血管生成的肽及其新用途。 更具体地，本发明涉及促进血管发生的肽，以及该肽用于促进血管发生和预防或治疗血管发生相关疾病的用途。 本发明的肽对促进血管生成具有极好的效果。 因此，用于预防或治疗血管生成相关疾病和用于制备皮瓣，伤口和烧伤愈合的再生，人造皮肤的植入和用于移植的血管的制备是有用的。
-
公开(公告)号：WO2011119009A2
公开(公告)日：2011-09-29
申请号：PCT/KR2011/002081
申请日：2011-03-25
Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SOOKMYUNG WOMEN'S UNIVERSITY , IL-YANG PHARM. CO., LTD , SAMSUNGN LIFE WELFARE FOUNDATION , CHO, Dae Ho , BANG, Sa Ik , PARK, Jeong Min , YOON, Sun Young , KIM, Sang Yoon , LEE, Ha Rum , PARK, Yoo Rim , SON, Juah
Inventor： CHO, Dae Ho , BANG, Sa Ik , PARK, Jeong Min , YOON, Sun Young , KIM, Sang Yoon , LEE, Ha Rum , PARK, Yoo Rim , SON, Juah
CPC classification number: C07K5/101 , A61K38/00 , A61K38/07 , A61K38/08 , C07K5/10 , C07K7/06 , C07K2319/00 , C07K2319/50
Abstract: The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial skin and preparation of blood vessels for transplantation.
Abstract translation: 本发明涉及促进血管生成的肽及其新用途。 更具体地，本发明涉及促进血管发生的肽，以及该肽用于促进血管发生和预防或治疗血管发生相关疾病的用途。 本发明的肽对促进血管生成具有极好的效果。 因此，用于预防或治疗血管生成相关疾病和用于制备皮瓣，伤口和烧伤愈合的再生，植入人造皮肤和制备用于移植的血管是有用的。
-
公开(公告)号：WO2010041863A2
公开(公告)日：2010-04-15
申请号：PCT/KR2009005714
申请日：2009-10-07
Applicant: IND ACADEMIC COOP , SAMSUNG LIFE WELFARE FOUND , CHO DAE HO , BANG SA IK , SONG SEOK BEAN , CHEON SO YOUNG , JUNG MIN KYUNG , PARK YOO RIM
Inventor： CHO DAE HO , BANG SA IK , SONG SEOK BEAN , CHEON SO YOUNG , JUNG MIN KYUNG , PARK YOO RIM
IPC: C12N5/077
CPC classification number: C12N5/0653 , C12N2500/25 , C12N2501/39 , C12N2501/82
Abstract: The present invention relates to an adipocyte differentiation medium composition and a method of differentiating preadipocytes into adipocytes using the same. The adipocyte differentiation medium composition is characterised in that it comprises insulin, DHEA (dehydroepiandrosterone) and histamine. Said medium composition achieves smoother distribution and more stable settling of differentiated adipocytes in comparison with conventional adipocyte differentiation medium compositions, thereby maximising adipocytic cell viability. Furthermore, the DHEA and histamine used in said medium composition is more cost-efficient than conventional adipocyte differentiation medium compositions that rely on dexamethasone and isobutylmethylxanthine.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.017 seconds)
